Laboratory Corporation of America Holdings (NYSE:LH) : Traders are bullish on Laboratory Corporation of America Holdings (NYSE:LH) as it has outperformed the S&P 500 by a wide margin of 2.19% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.75%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.05% in the last 1 week, and is up 3.84% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 10.76% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $135.63 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $128.98 and the 200 Day Moving Average price is recorded at $119.40.
The stock has recorded a 20-day Moving Average of 4.88% and the 50-Day Moving Average is 5.88%.
Laboratory Corporation of America Holdings (NYSE:LH): stock turned positive on Friday. Though the stock opened at $132.79, the bulls momentum made the stock top out at $135.63 level for the day. The stock recorded a low of $132.41 and closed the trading day at $135.3, in the green by 2.52%. The total traded volume for the day was 1,271,558. The stock had closed at $131.97 in the previous days trading.
In an insider trading activity,The director officer (President & CEO) of Laboratory Corp Of America Holdings, King David P sold 196,400 shares at $128.42 on June 13, 2016. The Insider selling transaction had a total value worth of $25,221,688. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.